We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

This study is currently recruiting participants.
Verified November 2017 by Janssen Research & Development, LLC
Sponsor:
ClinicalTrials.gov Identifier:
NCT01517802
First Posted: January 25, 2012
Last Update Posted: November 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Janssen Research & Development, LLC
  Purpose
The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 6 years.

Condition Intervention Phase
Metastatic Castration-resistant Prostate Cancer Metastatic Breast Cancer Drug: Abiraterone acetate Drug: Prednisone Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study

Resource links provided by NLM:


Further study details as provided by Janssen Research & Development, LLC:

Primary Outcome Measures:
  • The number of participants affected by a serious adverse event [ Time Frame: Up to 30 days after the last dose of study drug ]

Estimated Enrollment: 300
Actual Study Start Date: March 28, 2012
Estimated Study Completion Date: April 9, 2018
Estimated Primary Completion Date: April 9, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Abiraterone acetate
Patients will continue the same treatment regimen they were receiving during their participation in the previous abiraterone acetate clinical study.
Drug: Abiraterone acetate
Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
Drug: Prednisone
Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily

Detailed Description:
This is a nonrandomized (individuals will not be assigned by chance to study treatments), open-label (individuals will know the identity of study treatments), long-term safety follow-up study of abiraterone acetate in approximately 300 patients from other completed abiraterone acetate clinical studies. Patients must have received at least 3 months of treatment with abiraterone acetate and a low-dose corticosteroid and, based on investigator assessment, may benefit from continued treatment. This study will consist of a screening period followed by open-label treatment of continued abiraterone acetate access. The patients will continue with the same abiraterone acetate and low-dose corticosteroid dosing regimen they were receiving in the previous abiraterone acetate clinical study until the investigator determines that the patient is no longer receiving benefit or the sponsor terminates the study. Patients can be withdrawn from the study if an alternative access (eg, patient-assistance program or commercial source of abiraterone acetate) is available and feasible. Each cycle of treatment will be 28 days. Investigators will monitor and assess the patients for response to treatment or progression according to routine practice or as clinically indicated to determine whether continued treatment with abiraterone acetate is warranted. No efficacy data are being collected. Safety will be monitored throughout the study for a maximum duration of 6 years. End-of-study assessments will be performed at least 30 days after the last dose of abiraterone or upon early withdrawal.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Currently participating in an abiraterone acetate clinical study considered complete and had received at least 3 months of treatment with abiraterone acetate tablets.

Exclusion Criteria:

  • Medical conditions that require hospitalization.
  • Any condition or situation which, in the opinion of the investigator, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01517802


Contacts
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: JNJ.CT@sylogent.com

  Hide Study Locations
Locations
United States, Colorado
University of Colorado Cancer Center, Anschultz Cancer Pavilion Completed
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale Medical Group Withdrawn
New Haven, Connecticut, United States, 06520
United States, Louisiana
Hematology Oncology Specialists Completed
Marrero, Louisiana, United States, 70072
United States, Maryland
Sidney Kimmel Cancer Center at John Hopkins Withdrawn
Baltimore, Maryland, United States, 21205
United States, Massachusetts
Massachusetts General Hospital Cancer Center Completed
Boston, Massachusetts, United States, 02114
United States, Nebraska
GU Research Network Completed
Omaha, Nebraska, United States, 68130
United States, New York
North Shore Hem-onc Association Completed
East Setauket, New York, United States, 11733
Cornell Clinical Trials Unit - Weill Medical College of Cornell University Recruiting
New York, New York, United States, 10021
United States, South Carolina
Carolina Urologic Research Center Completed
Myrtle Beach, South Carolina, United States, 29572
United States, Tennessee
Chattanooga Oncology & Hematology Associates, PC Completed
Chattanooga, Tennessee, United States, 37404
United States, Texas
Texas Oncology - Sammons Cancer Center Completed
Dallas, Texas, United States, 75246
University of Texas MD Anderson Cancer Center Active, not recruiting
Houston, Texas, United States, 77030
Australia
St George Private Hospital Completed
Kogarah, Australia, 2217
Ashford Cancer Centre Active, not recruiting
Kurralta Park, Australia, 5037
HOCA @ Mater Completed
South Brisbane, Australia, 4121
St John of God Hospital Subiaco Active, not recruiting
Subiaco, Australia, 6008
Belgium
ZNA Middelheim Completed
Antwerpen, Belgium, 2020
Germany
Urologikum Hamburg Completed
Hamburg, Germany, 22399
Spain
Hospital Germans Trias y Pujol Active, not recruiting
Barcelona, Spain, 08916
Sweden
Akademiska Sjukhuset Recruiting
Uppsala, Sweden, 751 85
United Kingdom
Beatson West Of Scotland Cancer Centre Withdrawn
Glasgow, United Kingdom, G12 0YN
Newcastle-Upon-Tyne Hospitals NHS Foundation Trust Completed
Newcastle Upon Tyne, United Kingdom, NE7 7DN
East and North Hertfordshire NHS Trust Active, not recruiting
Northwood, United Kingdom, HA6 2RN
The Royal Marsden NHS Trust Sutton Active, not recruiting
Sutton, United Kingdom, SM2 5PT
Velindre NHS Trust Completed
Whitchurch, United Kingdom, CF14 2TL
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
  More Information

Additional Information:
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT01517802     History of Changes
Other Study ID Numbers: CR100797
212082PCR3010 ( Other Identifier: Janssen Research & Development, LLC )
2011-005243-28 ( EudraCT Number )
First Submitted: January 23, 2012
First Posted: January 25, 2012
Last Update Posted: November 16, 2017
Last Verified: November 2017

Keywords provided by Janssen Research & Development, LLC:
Metastatic castration-resistant prostate cancer
Metastatic breast cancer
Abiraterone acetate
Low-dose corticosteroid treatment
Long-term access

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Prednisone
Abiraterone Acetate
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormone Antagonists
Cytochrome P-450 Enzyme Inhibitors